Cost Benefit Assessment of Pharmaceutical Products

Karl E. Peace; Harvey Zimmerman

doi:10.1177/009286158802200301

Cost Benefit Assessment of Pharmaceutical Products

Karl E. Peace
, Harvey Zimmerman

Biostatistics, Epidemiology & Environmental Health Sciences

Research output: Contribution to journal › Article › peer-review

1 Scopus citations

Abstract

This article was published in Therapeutic Innovation and Regulatory Science.

Original language	American English
Journal	Therapeutic Innovation and Regulatory Science
Volume	22
DOIs	https://doi.org/10.1177/009286158802200301
State	Published - Jul 1 1988

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Disciplines

Public Health
Biostatistics

Keywords

Cost benefit assessment
Pharmaceutical products

Access to Document

10.1177/009286158802200301License: Unspecified

Cite this

@article{86739523a1ca44d7b0d82685c7fa1e91,

title = "Cost Benefit Assessment of Pharmaceutical Products",

abstract = " This article was published in Therapeutic Innovation and Regulatory Science. ",

keywords = "Cost benefit assessment, Pharmaceutical products",

author = "Peace, \{Karl E.\} and Harvey Zimmerman",

note = "Subscription and open access journals from SAGE Publishing, the world's leading independent academic publisher.",

year = "1988",

month = jul,

day = "1",

doi = "10.1177/009286158802200301",

language = "American English",

volume = "22",

journal = "Therapeutic Innovation and Regulatory Science",

issn = "2168-4790",

publisher = "Springer Science and Business Media Deutschland GmbH",

}

TY - JOUR

T1 - Cost Benefit Assessment of Pharmaceutical Products

AU - Peace, Karl E.

AU - Zimmerman, Harvey

N1 - Subscription and open access journals from SAGE Publishing, the world's leading independent academic publisher.

PY - 1988/7/1

Y1 - 1988/7/1

N2 - This article was published in Therapeutic Innovation and Regulatory Science.

AB - This article was published in Therapeutic Innovation and Regulatory Science.

KW - Cost benefit assessment

KW - Pharmaceutical products

UR - https://doi.org/10.1177/009286158802200301

U2 - 10.1177/009286158802200301

DO - 10.1177/009286158802200301

M3 - Article

SN - 2168-4790

VL - 22

JO - Therapeutic Innovation and Regulatory Science

JF - Therapeutic Innovation and Regulatory Science

ER -

Cost Benefit Assessment of Pharmaceutical Products

Abstract

UN SDGs

Disciplines

Keywords

Access to Document

Other files and links

Fingerprint

Cite this